Connection

PEDRO PIEDRA to Adolescent

This is a "connection" page, showing publications PEDRO PIEDRA has written about Adolescent.
Connection Strength

0.567
  1. Viral Load of Severe Acute Respiratory Syndrome Coronavirus 2 in Adults During the First and Second Wave of Coronavirus Disease 2019 Pandemic in Houston, Texas: The Potential of the Superspreader. J Infect Dis. 2021 05 20; 223(9):1528-1537.
    View in: PubMed
    Score: 0.049
  2. A Cross-sectional Surveillance Study of the Frequency and Etiology of Acute Respiratory Illness Among Pregnant Women. J Infect Dis. 2018 07 13; 218(4):528-535.
    View in: PubMed
    Score: 0.040
  3. A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age. J Infect Dis. 2016 Feb 01; 213(3):411-22.
    View in: PubMed
    Score: 0.033
  4. Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine. 2013 Jan 07; 31(3):524-32.
    View in: PubMed
    Score: 0.027
  5. Role of neutralizing antibodies in adults with community-acquired pneumonia by respiratory syncytial virus. Clin Infect Dis. 2012 Apr; 54(7):905-12.
    View in: PubMed
    Score: 0.026
  6. Direct and indirect effectiveness of influenza vaccination delivered to children at school preceding an epidemic caused by 3 new influenza virus variants. J Infect Dis. 2010 Dec 01; 202(11):1626-33.
    View in: PubMed
    Score: 0.023
  7. Effects of oseltamivir on influenza-related complications in children with chronic medical conditions. Pediatrics. 2009 Jul; 124(1):170-8.
    View in: PubMed
    Score: 0.021
  8. Societal and economic consequences of influenza. Manag Care. 2008 Oct; 17(10 Suppl 10):8-14.
    View in: PubMed
    Score: 0.020
  9. The search for adenovirus 14 in children in Houston, Texas. Pediatr Infect Dis J. 2008 Jul; 27(7):653-4.
    View in: PubMed
    Score: 0.020
  10. Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children. Pediatrics. 2007 Sep; 120(3):e553-64.
    View in: PubMed
    Score: 0.019
  11. Human metapneumovirus and respiratory syncytial virus infections in older children with cystic fibrosis. Pediatr Pulmonol. 2007 Jan; 42(1):66-74.
    View in: PubMed
    Score: 0.018
  12. Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial. Pediatrics. 2005 Sep; 116(3):e397-407.
    View in: PubMed
    Score: 0.016
  13. Epidemiology and genotypic diversity of rhinovirus in school-age children with acute respiratory illnesses seeking medical care. J Clin Virol. 2025 Aug; 179:105806.
    View in: PubMed
    Score: 0.016
  14. Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine. 2005 Feb 18; 23(13):1540-8.
    View in: PubMed
    Score: 0.016
  15. Influenza C virus in U.S. children with acute respiratory infection 2016-2019. J Clin Virol. 2024 10; 174:105720.
    View in: PubMed
    Score: 0.015
  16. Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine. 2003 Jul 28; 21(24):3479-82.
    View in: PubMed
    Score: 0.014
  17. Clinical Presentation and Severity of Adenovirus Detection Alone vs Adenovirus Co-detection With Other Respiratory Viruses in US Children With Acute Respiratory Illness from 2016 to 2018. J Pediatric Infect Dis Soc. 2022 Oct 25; 11(10):430-439.
    View in: PubMed
    Score: 0.013
  18. NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge. Vaccine. 2020 11 25; 38(50):7892-7896.
    View in: PubMed
    Score: 0.012
  19. Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med. 2020 12 10; 383(24):2320-2332.
    View in: PubMed
    Score: 0.012
  20. Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants. N Engl J Med. 2020 07 30; 383(5):426-439.
    View in: PubMed
    Score: 0.012
  21. Safety and Immunogenicity of a Respiratory Syncytial Virus Fusion (F) Protein Nanoparticle Vaccine in Healthy Third-Trimester Pregnant Women and Their Infants. J Infect Dis. 2019 10 22; 220(11):1802-1815.
    View in: PubMed
    Score: 0.011
  22. A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age. Vaccine. 2017 06 27; 35(30):3749-3759.
    View in: PubMed
    Score: 0.009
  23. Isolation of adenovirus type 7 from the urine of children with acute hemorrhagic cystitis. Pediatr Infect Dis J. 1996 Jul; 15(7):633-4.
    View in: PubMed
    Score: 0.009
  24. Enhanced Genetic Characterization of Influenza A(H3N2) Viruses and Vaccine Effectiveness by Genetic Group, 2014-2015. J Infect Dis. 2016 10 01; 214(7):1010-9.
    View in: PubMed
    Score: 0.009
  25. Influenza Vaccine Effectiveness Against 2009 Pandemic Influenza A(H1N1) Virus Differed by Vaccine Type During 2013-2014 in the United States. J Infect Dis. 2016 May 15; 213(10):1546-56.
    View in: PubMed
    Score: 0.008
  26. Influenza virus pneumonia: pathogenesis, treatment, and prevention. Semin Respir Infect. 1995 Dec; 10(4):216-23.
    View in: PubMed
    Score: 0.008
  27. Factors associated with real-time RT-PCR cycle threshold values among medically attended influenza episodes. J Med Virol. 2016 Apr; 88(4):719-23.
    View in: PubMed
    Score: 0.008
  28. Influenza vaccine effectiveness in the United States during 2012-2013: variable protection by age and virus type. J Infect Dis. 2015 May 15; 211(10):1529-40.
    View in: PubMed
    Score: 0.008
  29. Detection of NH1N1 influenza virus in nonrespiratory sites among children. Pediatr Infect Dis J. 2014 Jan; 33(1):95-6.
    View in: PubMed
    Score: 0.007
  30. Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Dis. 2014 Feb; 58(3):319-27.
    View in: PubMed
    Score: 0.007
  31. Community-acquired pneumonia in Chile: the clinical relevance in the detection of viruses and atypical bacteria. Thorax. 2013 Nov; 68(11):1000-6.
    View in: PubMed
    Score: 0.007
  32. Rapid research response to the 2009 A(H1N1)pdm09 influenza pandemic (Revised). BMC Res Notes. 2013 May 03; 6:177.
    View in: PubMed
    Score: 0.007
  33. [Universal immunisation against influenza in paediatrics, yes or no?]. An Pediatr (Barc). 2013 Oct; 79(4):261.e1-261.e11.
    View in: PubMed
    Score: 0.007
  34. Picornavirus, the most common respiratory virus causing infection among patients of all ages hospitalized with acute respiratory illness. J Clin Microbiol. 2012 Feb; 50(2):506-8.
    View in: PubMed
    Score: 0.006
  35. Incidence of catheter-associated gram-negative bacteremia in children with short bowel syndrome. J Clin Microbiol. 1989 Jun; 27(6):1317-9.
    View in: PubMed
    Score: 0.005
  36. Safety of the intranasal, trivalent, live attenuated influenza vaccine (LAIV) in children with intermittent wheezing in an open-label field trial. Pediatr Infect Dis J. 2008 May; 27(5):444-52.
    View in: PubMed
    Score: 0.005
  37. Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003-2004. Vaccine. 2007 May 16; 25(20):4038-45.
    View in: PubMed
    Score: 0.005
  38. Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A(H1N1) and B epidemic in healthy children. Arch Pediatr Adolesc Med. 2004 Jan; 158(1):65-73.
    View in: PubMed
    Score: 0.004
  39. Estimating efficacy of trivalent, cold-adapted, influenza virus vaccine (CAIV-T) against influenza A (H1N1) and B using surveillance cultures. Am J Epidemiol. 2003 Aug 15; 158(4):305-11.
    View in: PubMed
    Score: 0.004
  40. Lower respiratory tract infections due to adenovirus in hospitalized Korean children: epidemiology, clinical features, and prognosis. Clin Infect Dis. 2001 May 15; 32(10):1423-9.
    View in: PubMed
    Score: 0.003
  41. Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA. 2000 Jan 26; 283(4):499-505.
    View in: PubMed
    Score: 0.003
  42. Disseminated adenovirus disease in immunocompromised and immunocompetent children. Clin Infect Dis. 1998 Nov; 27(5):1194-200.
    View in: PubMed
    Score: 0.003
  43. Age distribution of patients with medically-attended illnesses caused by sequential variants of influenza A/H1N1: comparison to age-specific infection rates, 1978-1989. Am J Epidemiol. 1991 Feb 01; 133(3):296-304.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.